Related Experiment Video
Updated: Aug 15, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents
Gary M Coppola1, Robert E Damon, J Bruce Eskesen
1Department of Diabetes and Metabolism, Novartis Institutes for Biomedical Research, 100 Technology Square, Cambridge, MA 02139, USA. gary.coppola@novartis.com
Abstract:
A series of 1-alkyl-3-phenylthiourea analogues were prepared and evaluated as HDL- and Apo A-I-elevating and triglyceride-lowering agents. Several derivatives were superior to gemfibrozil. The optimal analogue (HDL376) was shown to raise HDL cholesterol in the rat, hamster, dog, and monkey models.
Related Concept Videos
Drug Biotransformation: Overview
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Bioavailability Enhancement: Drug Permeability Enhancement
Bioequivalence of Drugs: Drugs with Multiple Indications
Modified-Release Drug Delivery Systems: Bioavailability
Lipid-Lowering Drugs: Statins and Miscellaneous Agents